Papers
Algunos de los papers principales de nuestros integrantes
Nicolás Avellaneda
Short-term outcomes of surgical treatment for primary ileocaecal Crohn’s disease: Results of the Crohn’s(urg) study, a multicentre, retrospective, comparative analysis between inflammatory and complicated phenotypes
Short and long-term outcomes of surgery for inflammatory (uncomplicated) ileocecal Crohn’s disease: Multicentric retrospective analysis of 211 patients
Rodeando al enemigo: colectomía derecha laparoscópica por enfermedad de Crohn estenosante y fistulizante
Calidad de vida en pacientes con enfermedad de Crohn ileocecal posterior a tratamiento quirúrgico
Tips and tricks for a minimally invasive approach for complicated ileocaecal Crohn’s disease – A video vignette
Tips and tricks to perform a transanal ileal pouch-anal anastomosis in ulcerative colitis patients-A Video Vignette
Short-Term Results of Operative Treatment of Primary Ileocecal Crohn’s Disease: Retrospective, Comparative Analysis between Early (Luminal) and Complicated Disease
Earlier surgery is associated to reduced postoperative morbidity in ileocaecal Crohn’s disease: Results from SURGICROHN – LATAM study
Risk factors for major complications after surgical treatment of primary ileocecal Crohn’s disease. A multicentric Latin American experience
Controversies in IPAA for Ulcerative Colitis: A Systematic Review of Different Anastomotic Techniques
Crossing barriers: the burden of inflammatory bowel disease across Western Europe
Juan Lasa
Endoscopic scoring system utilization for inflammatory bowel disease activity assessment: A multicenter real-world study from Argentina.
Lasa J, Smolarczuk A, Navar S, Ponce C, Galvarini M, Orellana D, Caruso E, Espinosa F, Meligrana N, Rainero G, Correa G, Yantorno M, Garbi M, Giraudo F, Martínez S, García L, Marceno F, Marturano V, Reyes K, Steinberg L, Pereyra L, Olivera P.
Gastroenterol Hepatol. 2024 Mar;47(3):253-261. doi: 10.1016/j.gastrohep.2023.06.002. Epub 2023 Jun 15.PMID: 37330213 English, Spanish.
Opportunistic Infections in Patients with Inflammatory Bowel Disease Treated with Advanced Therapies: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Olivera PA, Lasa JS, Zubiaurre I, Jairath V, Abreu MT, Rubin DT, Reinisch W, Magro F, Rahier JF, Danese S, Rabaud C, Peyrin-Biroulet L.
J Crohns Colitis. 2023 Mar 18;17(2):199-210. doi: 10.1093/ecco-jcc/jjac133.PMID: 36087107
Treatment Adherence in Inflammatory Bowel Disease Patients from Argentina: A Multicenter Study.
Lasa J, Correa G, Fuxman C, Garbi L, Linares ME, Lubrano P, Rausch A, Toro M, Yantorno M, Zubiaurre I, Peyrin-Biroulet L, Olivera P.
Gastroenterol Res Pract. 2020 Jan 17;2020:4060648. doi: 10.1155/2020/4060648. eCollection 2020.PMID: 32411197 Free PMC article.
Safety of S1P Modulators in Patients with Immune-Mediated Diseases: A Systematic Review and Meta-Analysis.
Lasa JS, Olivera PA, Bonovas S, Danese S, Peyrin-Biroulet L.
Drug Saf. 2021 Jun;44(6):645-660. doi: 10.1007/s40264-021-01057-z. Epub 2021 Mar 5.PMID: 33666900
Endoscopically Active Ulcerative Colitis Is Associated With Asymptomatic Atherosclerotic Vascular Disease: A Case-Control Study.
Lasa J, Nazario E, De Sanctis G, Fernández Recalde M, Redondo JP, Montañana J, Spernanzoni F, Zubiaurre I, Olivera PA.
Inflamm Bowel Dis. 2023 Sep 21:izad217. doi: 10.1093/ibd/izad217. Online ahead of print.PMID: 37738567
Incidence and prevalence of inflammatory bowel diseases in a population from Buenos Aires, Argentina.
Olivera PA, Parks ML, Pellegrini D, Finn B, Gutierrez R, Zubiaurre I, Lasa J.
Gastroenterol Hepatol. 2023 Oct 6:S0210-5705(23)00440-5. doi: 10.1016/j.gastrohep.2023.09.012. Online ahead of print.PMID: 37806345 English, Spanish.
Impact of an Educational Mobile App on Inflammatory Bowel Disease Colonoscopy Report Quality.
Pereyra L, Gomez EE, Gonzalez RA, Smolarczuk A, Ponce CS, Navar S, Schlottmann F, Steinberg L, Lasa J.
Dig Dis Sci. 2023 Dec;68(12):4360-4367. doi: 10.1007/s10620-023-08120-y. Epub 2023 Oct 5.PMID: 37796403
Review article: Risk of cardiovascular events in patients with inflammatory bowel disease receiving small molecule drugs.
Olivera PA, Lasa JS, Peretto G, Zuily S, Danese S, Peyrin-Biroulet L.
Aliment Pharmacol Ther. 2023 Jun;57(11):1231-1248. doi: 10.1111/apt.17509. Epub 2023 Apr 10.PMID: 37038269 Review.
Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis.
Olivera PA, Lasa JS, Bonovas S, Danese S, Peyrin-Biroulet L.
Gastroenterology. 2020 May;158(6):1554-1573.e12. doi: 10.1053/j.gastro.2020.01.001. Epub 2020 Jan 9.PMID: 31926171
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial.
Feagan BG, Sands BE, Sandborn WJ, Germinaro M, Vetter M, Shao J, Sheng S, Johanns J, Panés J; VEGA Study Group.
Lancet Gastroenterol Hepatol. 2023 Apr;8(4):307-320. doi: 10.1016/S2468-1253(22)00427-7. Epub 2023 Feb 1.PMID: 36738762 Clinical Trial.
